Gene therapy continues to advance
FDA’s Advisory Committee unanimously recommends that Luxturna from the American gene therapy company Spark Therapeutics will be approved for the treatment of an unusual form of eye disease called retinitis pigmentosaRetinitis pigmentosa is a genetic disease. Symptoms comprise of, among other things, involuntary eye movements, tunnel vision and loss of night vision. The disease can lead to complete blindness. No effective treatment has previously existed, but the recommendation from the FDA’s Advisory Committee probably means that the FDA (the Federal Drug Administration) will approve
